Standard BioTools(US:LAB) Newsfilter·2024-05-28 20:01Core Insights - Standard BioTools Inc. has acquired the LSAXT system from Carterra to enhance the validation of its SomaScan Platform, which focuses on measuring kinetic properties of SOMAmer Reagents and providing detailed information on protein binding and biomarker characterization [1][2][3] Company Overview - Standard BioTools Inc. (Nasdaq:LAB), formerly known as Fluidigm Corporation, specializes in next-generation technologies that aid biomedical researchers in developing medicines more efficiently. The company utilizes proprietary mass cytometry and microfluidics technologies to deliver reliable insights in health and disease [4] - Carterra is a leading provider of high-throughput technologies aimed at accelerating the discovery of novel therapeutic candidates. Its LSAXT system is designed to deliver significantly higher throughput and efficiency compared to existing platforms [6] Product and Technology Details - The SomaScan Platform is a high-throughput proteomics technology that allows comprehensive analysis of proteomic biomarkers, enhancing the research capabilities for scientists [2] - The LSAXT system will be instrumental in verifying the quality of SomaScan 11K Assay reagents and will support future content expansion of the platform, thereby increasing its value to researchers [2][3] - The LSAXT system is noted for its ability to provide more data in a shorter time frame, which will help Standard BioTools identify precise binding sites on proteins and discover new biomarkers [3] Leadership Statements - The CEO of Carterra expressed enthusiasm about the collaboration with Standard BioTools, emphasizing the importance of measuring kinetic properties for a deeper understanding of reagent-protein interactions [3] - The President and CEO of Standard BioTools highlighted the focus on ensuring precision and specificity in the SomaScan Platform, which will be enhanced by the capabilities of the LSAXT system [4]